Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774758 · ClinicalTrials.gov registry record
Biomarkers for Risk Stratification in Lung Cancer
A clinical trial of Non-Small Cell Lung Cancer and Nodule Solitary Pulmonary, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 590
- Enrollment target
- 3
- Study locations
NCT03774758 is a study of Non-Small Cell Lung Cancer and Nodule Solitary Pulmonary that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 590 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (10% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT03774758, a study of Non-Small Cell Lung Cancer and Nodule Solitary Pulmonary, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 590 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Guardant Health ct-DNA LUNAR assay
Study Locations (3)
California
- Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
- San Francisco VA Medical Center - San Francisco
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 590 participants |
| Start Date | 2017-12-17 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03774758
The ClinicalTrials.gov registry entry for NCT03774758 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 590 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (10% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Guardant Health ct-DNA LUNAR assay is the first listed.
NCT03774758 reports 3 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03774758 about?
NCT03774758 is a clinical study titled "Biomarkers for Risk Stratification in Lung Cancer". This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populat...
What is the current status of trial NCT03774758?
This trial is currently recruiting. The enrollment target is 590 participants. The study started on 2017-12-17. Estimated completion is 2025-12-31.
What conditions does trial NCT03774758 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Nodule Solitary Pulmonary.
What interventions are being tested in trial NCT03774758?
The interventions under investigation include: Guardant Health ct-DNA LUNAR assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03774758?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03774758 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.